“…Moreover, expression of EGF, TGF-and heparin binding-EGF (HB-EGF) as well as their respective receptors EGFR and ErbB2, have been detected in the intimal thickening and medial smooth muscle cells (SMCs) of atherosclerotic lesions, whereas little or no presence of these molecules is observed in the cells of healthy vessels (Dreux et al, 2006). EndoMT is not only recognized as a phenomenon that occurs during cardiac fibrosis and intimal thickening formation observed in atherosclerosis and restenosis but also in heart and vascular development (Arciniegas et al, 2000;Mironov et al, 2005), pulmonary arterial hypertension (Arciniegas et al, 2007;Morrell et al, 2009;Sakao et al, 2010), cardiac (Goumans et al, 2008) and kidney fibrosis , hyperthrophic scarring (XiQiao et al, 2009), diabetic nephropathy (Li & Bertram, 2010), and during cancer progression . However, there are no studies about the specific role of EGF signalling pathway in the EndoMT process.…”